SOST

SOST Molekülinformation

Englischer Name	Sclerostin	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	6	Target-Alias	Sclerostin，UNQ2976/PRO7455/PRO7476，SOST，Sclerosteosis，DAND6，SOST1，VBCH，CDD
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Sclerostin
Target-Alias	Sclerostin，UNQ2976/PRO7455/PRO7476，SOST，Sclerosteosis，DAND6，SOST1，VBCH，CDD
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	6
Höchste Forschungs- und Entwicklungsphase	Approved

SOST Produktliste

Attribut
Protein (2)
Produktbibliothek
Online (2)
Spezies
Human (2)
Etikett
His Tag (2)
Marker
Unconjugated (1)Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HST-H5245	Human	HEK293	Human SOST / Sclerostin Protein, His Tag, low endotoxin (HPLC verified)				In den Warenkorb legen
SOT-H8245	Human	HEK293	Biotinylated Human SOST / Sclerostin Protein, His Tag, ultra sensitivity (primary amine labeling)				In den Warenkorb legen

Gesamtmenge2

SOST Molekülhintergrund

Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008]

SOST Molekülalias

SOST,VBCH

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Setrusumab	UX143; NOV-3; MOR-05813; BPS-804	Phase 3 Clinical	Morphosys Ag, Novartis Pharma Ag	Bone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Osteoporosis; Renal Insufficiency, Chronic	Details
AGA-2115	AGA2115; AGA-2115	Phase 2 Clinical	Angitia Biopharmaceuticals (Guangzhou) Ltd	Osteogenesis Imperfecta	Details
AGA-2118	AGA-2118	Phase 2 Clinical	Angitia Biomedicines Ltd	Osteoporosis; Osteoporosis, Postmenopausal	Details
Resugosbart	SHR-1222	Phase 1 Clinical	Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd	Osteoporosis; Osteoporosis, Postmenopausal	Details
Romosozumab biosimilar(Zhuhai Federation Biomedicine)		Phase 1 Clinical	Zhuhai Federation Biomedicine Co Ltd	Osteoporosis, Postmenopausal	Details
Blosozumab	TST002; LY-2541546; TST002-IgG4	Phase 1 Clinical	Eli Lilly And Company	Osteoporosis; Osteoporosis, Postmenopausal	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Romosozumab	CDP-7851; AMG-785	Approved		Evenity, EVENITY	Japan	Osteoporosis	Amgen Inc	2019-01-08	Bone Diseases, Metabolic; Fractures, Bone; Osteogenesis Imperfecta; Osteoporosis; Osteoporosis, Postmenopausal	Details